Recurrent tuberculosis: Relapse, reinfection, and HIV

Journal of Infectious Diseases

Volumn 201, Issue 5, 2010, Pages 653-655

  Chaisson, Richard E ^a   Churchyard, Gavin J ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AURUM INSTITUTE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

COMORBIDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOTE; POSTPRIMARY TUBERCULOSIS; PRIORITY JOURNAL; RECURRENT INFECTION; REINFECTION; RELAPSE; SUPERINFECTION; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; RECURRENCE; TUBERCULOSIS;

EID: 76449100099     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/650531     Document Type: Note

References (24)

1. World Health Organization. WHO Report 2009. Global tuberculosis control: epidemiology, strategy, financing. http://www.who.int/tb/publications/global- report/2009/pdf/full-report.pdf. Published 24 March 2009. Accessed 23 January 2010.
2. Sterling TR, Alwood K, Gachuhi R, et al. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS 1999; 13:1899-1904.
3. Vernon A, Burman W, Benator D, Khan A, Bozeman L, for the Tuberculosis Trials Consortium. Acquired rifamycin monoresistance in patients with HIV-related tuberculosistreated with once-weekly rifapentine and isoniazid. Lancet 1999; 353:1843-1847.
4. Small PM, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993; 328:1137-1144.
5. Korenromp EL, Scano F,Williams BG, Dye C, Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis 2003; 37:101-112.
6. Corbett EL, Bandason T, Cheung YB, et al. Prevalent infectious tuberculosis in Harare, Zimbabwe: burden, risk factors and implications for control. Int J Tuberc Lung Dis 2009; 13:1231-1237.
7. Narayanan S, Swaminathan S, Supply P, et al. Impact of HIV infection on the recurrence of tuberculosis in South India. J Infect Dis 2010; 201:691-703 (in this issue).
8. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575-1580.
9. Glynn JR, Murray J, Bester A, Nelson G, Shearer S, Sonnenberg P. High rates of recurrence in HIV-infected and HIV-uninfected patients with tuberculosis. J Infect Dis 2010; 201: 704-711 (in this issue).
10. Verver S, Warren RM, Beyers N, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005; 171: 1430-1435.
11. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358: 1687-1693.
12. Charalambous S, Grant AD, Moloi V, et al. Contribution of reinfection to recurrent tuberculosis in South African gold miners. Int J Tuberc Lung Dis 2008; 12:942-948.
13. Golub JE, Durovni B, King BS, et al. Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2008; 22:2527-2533.
14. Korenromp EL, Scano F,Williams BG, Dye C, Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis 2003; 37:101-112.
15. Rosenthal IM, Zhang M, Williams KN, et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007; 4(12):e344.
16. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008; 177: 787-792.
17. FitzgeraldDW, Desvarieux M, Severe P, Joseph P, Johnson WD Jr, Pape JW. Effect of posttreatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet 2000; 356(9240): 1470-1474.
18. Churchyard GJ, Fielding K, Charalambous S, et al. Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? AIDS 2003; 17:2063-2070.
19. Nahid P, Gonzalez LC, Rudoy I, et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007; 175:1199-1206.
20. Abdool Karim SS, Naidoo K, Grobler A, et al. Effect of initiating antiretroviral therapy during tuberculosis treatment in HIV-infected individuals: results of a randomized controlled trial in TB-HIV co-infected patients in South Africa (SAPiT Study). N Engl J Med 2010, in press.
21. Velasco M, Castilla V, Sanz J, et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009; 50(2):148-152.
22. World Health Organization. WHO Policy on TB infection control in health-care facilities, congregate settings and households. Geneva, World Health Organization, 2009.
23. Mostowy S, Tsolaki AG, Small PM, Behr MA. The in vitro evolution of BCG vaccines. Vaccine 2003; 21:4270-4274.
24. Barker LF, Brennan MJ, Rosenstein PK, Sadoff JC. Tuberculosis vaccine research: the impact of immunology. Curr Opin Immunol 2009; 21(3):331-338.